Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3328639 | Critical Reviews in Oncology/Hematology | 2015 | 10 Pages |
•We examine the recent findings on the mechanisms of drug resistance in bladder cancer.•We report the methods employed in the assessment of these markers.•We highlight the potential strategies to overcome such resistance.
SummaryThe combination chemotherapies with methotrexate plus vinblastine, doxorubicin and cisplatin (MVAC or CMV regimens) or gemcitabine plus cisplatin represent the standard as first-line therapy for patients with metastatic urothelial cancer. In Europe, vinflunine is an option for second-line therapy for patients progressed during first-line or perioperative platinum-containing regimen. Alternative regimens containing taxanes and/or gemcitabine may be valuated case by case. Furthermore, carboplatin should be considered in patients unfit for cisplatin both in the first and second-line setting. Based on these findings, a better comprehension of the mechanisms underlying the development of drug resistance in patients with bladder cancer will represent a major step forward in optimizing patients’ outcome. This article reviews the current knowledge of the mechanisms and emerging strategies to overcome resistance in patients with advanced urothelial cancer.